Want a little “surgical robotics” in your portfolio? Most people’s first instinct is Intuitive Surgical (ISRG). It’s the dominant leader with a rock-hard moat — and very expensive, forward P/E north of 40x. So you’re stuck: you want exposure, but you can’t pull the trigger.

The problem is a hidden assumption: you think “surgical robotics” is one market. It’s actually three, with wildly different valuations.

Three markets, three ways to buy

• Soft-tissue surgery (monopoly): ISRG’s turf — 60%+ share, razor/blade, profitable for decades. Best quality, priciest. You pay full price for certainty.
• Orthopedic surgery (oligopoly): the overlooked opportunity. Ortho giants like Stryker (SYK) and Globus Medical (GMED) use the robot in a completely different role — not as the main profit source, but as the “hook” that pulls high-margin implants.
• Specialty growth (emerging): names like PROCEPT (PRCT) making single-point breakthroughs in niche procedures — high growth, high volatility.

See those three layers, and the seemingly contradictory ask — “surgical robotics + a fair price” — suddenly has an answer.

The ortho secret: the robot is a “hook,” implants are the profit

Why can SYK and GMED trade at nearly half the multiple (forward P/E ~low-20s)?

Because in ortho, the surgical robot itself doesn’t need to make big money — it’s an account-control tool. Once a hospital installs Stryker’s Mako robot, the knee and hip implants around it are largely locked in. The robot is the hook that pulls the hospital into the ecosystem and locks in high-margin consumables long-term.

This logic mirrors ISRG’s razor/blade — equipment placed, compounding on downstream consumables — but the market prices the ortho giants far more rationally, because they’re large and steadily growing. If you want “surgical-robotics account-control logic + a reasonable price,” the answer is SYK/GMED, not ISRG.

Don’t treat a sector as a single stock

The core method here applies to any theme: when a “sector” contains a monopolist, oligopolists, and emerging challengers at once, don’t let one stock stand for the whole thing.

Want maximum quality and certainty, willing to pay up → ISRG. Want “surgical-robot exposure + reasonable price + steady compounding” → look at the SYK/GMED hook logic. Want niche high-growth and can stomach volatility → the specialty tier. Three asks, three answers — don’t blur them.

The leader being expensive doesn’t mean the theme has no reasonably-priced entrance. You just have to see “one market” as “three.”

Would you pay 40x for “surgical robotics,” or route in through the ortho giants’ “hook logic”?

(Independent industry and educational research, not investment advice. Companies named are illustrative examples, not recommendations. Data is from public sources and may change. The author and affiliates may hold positions in securities mentioned.)

— Adapted from Embodied Intelligence Investing, Deep Dive XIII: Surgical Robotics Cluster

#SurgicalRobotics #MedTech #EmbodiedAI